These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32486990)

  • 41. Overview of Drugs Used to Treat Opioid Use Disorder.
    Aschenbrenner DS
    Am J Nurs; 2018 Aug; 118(8):25. PubMed ID: 30048283
    [No Abstract]   [Full Text] [Related]  

  • 42. Buprenorphine for opioid dependence.
    Drug Ther Bull; 2007 Mar; 45(3):20-4. PubMed ID: 17405584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis.
    Durand L; Boland F; Harnedy N; Delargy Í; Scully M; Bourke M; Ebbitt W; Otero Vázquez M; Keenan E; Cousins G
    J Subst Use Addict Treat; 2023 Jun; 149():209029. PubMed ID: 37003538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The duration dilemma in opioid agonist therapy.
    Dhanda A; Salsitz EA
    J Opioid Manag; 2021; 17(4):353-358. PubMed ID: 34533830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary on Freelemyer et al. (2014): medication-assisted treatment in Africa-need is growing but response remains tepid.
    Obot IS
    Addiction; 2014 Jan; 109(1):33-4. PubMed ID: 24438111
    [No Abstract]   [Full Text] [Related]  

  • 49. Quality of primary care among individuals receiving treatment for opioid use disorder.
    Spithoff S; Kiran T; Khuu W; Kahan M; Guan Q; Tadrous M; Leece P; Martins D; Gomes T
    Can Fam Physician; 2019 May; 65(5):343-351. PubMed ID: 31088874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methadone and buprenorphine treatments in patients with schizophrenia.
    Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T
    Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511
    [No Abstract]   [Full Text] [Related]  

  • 51. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine.
    Madden L; Bojko MJ; Farnum S; Mazhnaya A; Fomenko T; Marcus R; Barry D; Ivanchuk I; Kolomiets V; Filippovych S; Dvoryak S; Altice FL
    Int J Drug Policy; 2017 Nov; 49():48-53. PubMed ID: 28957756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Better efficacy of buprenorphine and methadone in opioid dependence. Requirements for abstinence from non-opioids before starting treatment paid off].
    Hoffmann O; Frisell F; Ljungberg T
    Lakartidningen; 2014 Jan 29-Feb 4; 111(5):147-9. PubMed ID: 24624763
    [No Abstract]   [Full Text] [Related]  

  • 56. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.
    Alford DP; Compton P; Samet JH
    Ann Intern Med; 2006 Jan; 144(2):127-34. PubMed ID: 16418412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buprenorphine and methadone for opioid addiction during pregnancy.
    Mozurkewich EL; Rayburn WF
    Obstet Gynecol Clin North Am; 2014 Jun; 41(2):241-53. PubMed ID: 24845488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome evaluation of the opioid agonist maintenance treatment in Iran.
    Esmaeili HR; Ziaddinni H; Nikravesh MR; Baneshi MR; Nakhaee N
    Drug Alcohol Rev; 2014 Mar; 33(2):186-93. PubMed ID: 24428135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A truly patient-centred evaluation of opioid agonist treatment.
    Trujols J; Vicent-Gil M; Duran-Sindreu S; Portella MJ
    Lancet Psychiatry; 2023 Aug; 10(8):583. PubMed ID: 37479338
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.